Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs Viatris Inc (VTRS) Price & Performance

Alexandria Real Estate Equities IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs Viatris Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.16 (market cap $8.28B), while Viatris Inc trades at $16.31 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.3× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.

AREVTRS
Market Cap
$8.28B$18.69B
Sector
Real EstateHealth
52-Week High
$87.45$17.86
52-Week Low
$40.41$9.49
Enterprise Value
$20.98B$30.80B
Dividend Yield
5.99%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $48.35, down 2.79% today, with a bearish technical signal and mixed fundamentals. The stock shows a negative net income margin of -37.12% for 2025, though recent Q2 2026 FFO beat estimates. Analyst consensus is a 'Buy' with a $53.71 price target, but technical indicators suggest near-term pressure with support at $47 and resistance at $50.

Outlook remains cautious due to profitability challenges and high debt, but leasing momentum and strategic partnerships offer recovery potential. Risks include ongoing net losses and market volatility, while institutional interest and dividend payments provide some stability. Investors should weigh fundamental weaknesses against long-term real estate sector recovery prospects.

Viatris Inc

Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.

Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.

Returns comparison

Trailing returns across standard periods

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS